51. He L, He X, Lim LP, de Stanchina E, Xuan Z, et al. (2007) A microRNA component of the p53 tumour suppressor network. Nature 447: 1130–1134. 52. Sun F, Fu H, Liu Q, Tie Y, Zhu J, et al. (2008) Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett 582: 1564–1568. 53. Yamakuchi M, Ferlito M, Lowenstein CJ (2008) miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci U S A 105: 13421–13426. 54. Chen C, Wells AD (2007) Comparative Analysis of E2F Family Member Oncogenic Activity. PLoS One 2: e912. 55. Reimer D, Hubalek M, Kiefel H, Riedle S, Skvortsov S, et al. (2011) Regulation of transcription factor E2F3a and its clinical relevance in ovarian cancer. Oncogene. 56. Reimer D, Hubalek M, Riedle S, Skvortsov S, Erdel M, et al. (2010) E2F3a Is Critically Involved in Epidermal Growth Factor Receptor Directed Proliferation in Ovarian Cancer. Cancer Research 70: 4613–4623. 57. Kumar B, Cordell KG, Lee JS, Worden FP, Prince ME, et al. (2008) EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 26: 3128–3137. 58. Liping S, Ying W, Mingzhen X, Yuan L, Lei Y (2010) Up-regulation of survivin in oral squamous cell carcinoma correlates with poor prognosis and chemoresistance. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 110: 484–491. 59. Tran J, Master Z, Yu JL, Rak J, Dumont DJ, et al. (2002) A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci U S A 99: 4349–4354. 60. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, et al. (2000) Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 6: 127–134. miR-34a Inhibits HNSCC Tumor Growth 61. Kawasaki H, Toyoda M, Shinohara H, Okuda J, Watanabe I, et al. (2001) Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer 91: 2026–2032. 62. Preuss SF, Weinell A, Molitor M, Stenner M, Semrau R, et al. (2008) Nuclear survivin expression is associated with HPV-independent carcinogenesis and is an indicator of poor prognosis in oropharyngeal cancer. Br J Cancer 98: 627–632. 63. Swana HS, Grossman D, Anthony JN, Weiss RM, Altieri DC (1999) Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med 341: 452–453. 64. Livak KJ, Schmittgen TD (2001) Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2-[Delta][Delta]CT Method. Methods 25: 402–408. 65. Nor JE, Christensen J, Liu J, Peters M, Mooney DJ, et al. (2001) Up-Regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Res 61: 2183–2188. 66. Yadav A, Kumar B, Teknos TN, Kumar P (2011) Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins. Mol Cancer Ther 10: 1241–1251. 67. Yadav A, Kumar B, Datta J, Teknos TN, Kumar P (2011) IL-6 Promotes Head and Neck Tumor Metastasis by Inducing Epithelial-Mesenchymal Transition via the JAK-STAT3-SNAIL Signaling Pathway. Mol Cancer Res 9: 1658–1667. 68. Kumar P, Benedict R, Urzua F, Fischbach C, Mooney D, et al. (2005) Combination treatment significantly enhances the efficacy of antitumor therapy by preferentially targeting angiogenesis. Lab Invest 85: 756–767. PLoS ONE | www.plosone.org 13 May 2012 | Volume 7 | Issue 5 | e37601